Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
46 hedge funds and large institutions have $112M invested in Cidara Therapeutics in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 5 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
0% more funds holding
Funds holding: 46 → 46 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
27% less capital invested
Capital invested by funds: $154M → $112M (-$41.5M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$3.23M |
| 2 |
AIC
AWM Investment Company
New York
|
+$1.33M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$464K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$319K |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$230K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$3.12M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.78M |
| 3 |
DM
Deerfield Management
New York
|
-$584K |
| 4 |
SIM
Spark Investment Management
New York
|
-$245K |
| 5 |
B
Bailard
Foster City,
California
|
-$240K |
CDTX Hedge Fund Activity: Q1 2016 in Review
46 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q1 2016, worth a combined $112M — down 27% from $154M a quarter earlier.
Fund positioning in CDTX was balanced in Q1 2016: 5 funds opened new positions, 5 closed out, 14 added to existing stakes and 11 trimmed.
The largest buyer was BB Biotech, adding an estimated $3.23M. The largest seller was Goldman Sachs, cutting an estimated $3.12M.
- 46 institutional investors held Cidara Therapeutics (CDTX) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $112M of Cidara Therapeutics stock for Q1 2016, down 27% quarter-over-quarter.
- 5 funds opened new Cidara Therapeutics positions in Q1 2016 and 5 closed out, a net change of 0 holders.
- The largest Cidara Therapeutics buyer in Q1 2016 was BB Biotech, an estimated $3.23M added.
- The largest Cidara Therapeutics seller in Q1 2016 was Goldman Sachs, an estimated $3.12M sold.
Based on aggregated 13F filings for Q1 2016.